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 KEY POINTS: 
 The prevalence of PPI use in the UK general population is high and still increasing.  
 The majority of patients only use PPIs short term, with only 26% using them long-
term.  
 Clear attempts to step down long-term use were identified in two fifths of the 
patients, so there remain further opportunities for reducing the cost and side effects 
of PPI use through improving adherence to recommended withdrawal strategies. 
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Abstract: 1 
Purpose: To determine the prevalence and pattern of proton pump inhibitor (PPI) 2 
prescription, and the practices employed to reduce PPI use in the UK general population.  3 
Method: The UK’s Clinical Practice Research Database was used to identify individuals who 4 
were issued with ≥1 PPI prescription during the period 1990-2014. Point and period 5 
prevalence of PPI use were estimated annually. Additionally, new users of PPI therapy who 6 
had five years of follow-up data were included in a cohort analysis to describe patterns of 7 
cessation and duration of PPI use. 8 
Results: Both the period and point prevalence of PPI use increased between 1990 and 2014 9 
(period prevalence increased from 0.2% to 15.0% and point from 0.03 % to 7.7%). A total of 10 
596,334 new users of PPI therapy in the cohort study received 8,784,272 prescriptions. Of 11 
these, 26.7% used PPI therapy long-term (≥1 year continuously) while 3.9% remained on PPI 12 
therapy for five years. Clear attempts to step down dose were identified in 39.9% of long-13 
term users while this was 47% in patients whose initial indication did not mandate long-term 14 
use. 15 
Conclusion: A considerable increase in PPI use was observed in UK general practice. 60% of 16 
long-term PPI users did not have an attempt to discontinue or step down. Considerable 17 
opportunities may therefore exist to reduce the cost and side effects of PPI use through 18 
improving adherence to recommended withdrawal strategies.19 
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INTRODUCTION 20 
The introduction of proton pump inhibitors (PPIs) has revolutionised the management of 21 
acid-related gastrointestinal disorders1. In the United Kingdom (UK), 11,126 thousand 22 
prescriptions for PPIs were dispensed in 20002, and this increased to 43,127 thousand in 23 
20113. Although the expenditure on PPIs has decreased in the UK since 2006 as a result of 24 
government efforts to encourage the use of low-cost generic PPIs4,5, there has still been an 25 
overall increase in the total number of PPI prescriptions dispensed4. For instance, in 2010, 26 
PPIs became one of the top 20 drugs with the greatest net ingredient cost in the UK4. 27 
The importance of reducing any overuse of PPIs is not limited to the associated costs, but 28 
also to the risks of taking the drugs on a long-term basis6. As PPIs have become commonly 29 
used for long-term maintenance, concerns have been raised about the safety of such use 6. 30 
Studies have showed that PPI use is associated with malabsorption of vitamins and 31 
minerals7,8, an increased risk of infections, such as pneumonia9 and enteric infection10, and 32 
an increased fracture risk11,12. These potential side effects can be minimized through 33 
appropriate prescription practices in terms of stepping down the dose or stopping long-term 34 
treatment altogether. 35 
As a consequence of this dramatic increase in PPI use and the associated potential risks, 36 
clinical guidelines in the UK have recommended rationing the use of the PPI in the primary 37 
care setting, either by stepping down the dose or stopping treatment all together13. 38 
However, very few research studies have examined the extent to which the clinical guidelines 39 
are being followed in the UK 14–19. The aim of this study was to determine the prevalence of 40 
PPI use and assess the practices employed to reduce PPI use in the general UK population. It 41 
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is anticipated that research of this nature will help to inform future attempts to moderate the 42 
use of PPIs. 43 
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METHODS 44 
Study type and data source 45 
We conducted an observational study with repeated cross-sectional analyses to estimate the 46 
prevalence of PPI use annually and a cohort design to describe the patterns of PPI utilization 47 
by using data from the UK Clinical Practice Research Datalink (CPRD)20.  CPRD is a large 48 
database drawn from the computerised records of primary care practices throughout the UK 49 
and encompassing a representative sample of around 6% of UK population 21–23. The CPRD 50 
comprises data about patients’ medical diagnoses, GPs’ prescriptions, investigations, hospital 51 
referrals and discharges, together with basic demographic information. The information on 52 
prescriptions includes their issue dates, the drug prescribed, numeric daily dose, daily 53 
quantity and the number of packs/pack size prescribed. Many studies have validated CPRD 54 
for use in pharmacoepidemiological research21,24.  55 
Study population 56 
We studied  adult patients with at least one month of prospective records after either the 57 
date of their current registration or the date after the practice became “up to standard” 58 
(UTS) on CPRD21 whichever was the latest, and an “acceptable” registration status as defined 59 
by CPRD21 between 1st Jan 1990 and 31st December 2014. This population formed our 60 
denominator for studies of prevalence. Patients who received ≥1 PPI prescription(BNF 1.3.5 61 
25) were classified as exposed subjects in the study (i.e. the numerator).  62 
Prescription duration  63 
The earliest PPI prescription for each patient was considered their index date. Prescription 64 
duration was taken as the number of treatment days recorded by the GP, or calculated from 65 
the prescribed quantity and numeric daily dose prescribed. If information on both was 66 
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missing, the individual median duration was imputed. The duration was recalculated if the 67 
calculated prescription duration was less than or equal to seven days assuming that the 68 
prescription quantity was referring to the number of individual product packs prescribed. 69 
Prescribing patterns  70 
To describe the prescribing practices of long-term PPI use in general practice in term of 71 
discontinuation, stepping down or switching to histamine 2 receptor antagonists (H2RA), we 72 
identified new PPI therapy users i.e. patients with at least 12 months of registration on CPRD 73 
prior to their index date who had ≥ 5 years of prospective follow-up data. We  74 
The NICE guidelines13 were used to determine what constitutes expected long-term PPI 75 
use within this study. PPIs are used for the short-term management in conditions such as 76 
dyspepsia, gastro-oesophageal reflux disease (GORD), and gastric and duodenal ulcers. Long-77 
term PPI therapy is often prescribed to prevent recurrence of GORD complications, and as 78 
prophylactic therapy to prevent peptic ulcers in patients who are co-prescribed non-steroidal 79 
anti-inflammatory (NSAID) therapy13.  80 
Exposure to PPIs was considered to begin on the date of a prescription for them and end 81 
after its calculated duration unless another prescription was issued ≤30 days after this date in 82 
which case we considered exposure continuous. We refer to one set of continuous 83 
prescriptions as one course. Courses were classified as short (<12 months) or long (≥12 84 
months), this time period being chosen as 12 months is the minimum frequency with which 85 
NICE recommends that these prescriptions should be reviewed and stopped or stepped down 86 
if possible. Individuals receiving exclusively short courses were classified as short-term users 87 
while individuals who received at least one long course were classified as long-term users 88 
even if their records contained other short courses.  89 
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Discontinuation (no subsequent PPI prescription issued within 30 days after the end of 90 
the previous one) was categorized as temporary (patients subsequently re-prescribed PPI) or 91 
permanent (no further prescriptions received up to the end of the patient’s follow-up). A step 92 
down of PPI therapy was defined as a reduction in daily dose of the subsequent PPI 93 
prescription. If a following prescription was for a different PPI, the dose was converted to an 94 
equivalent dose based on the recommended dosing in the BNF25.  A successful step down 95 
was defined as maintaining the stepped down dose for 12 months from the step down date. 96 
Lastly, a switch to H2RA medication was defined as receiving H2RA prescription within one 97 
month before or after discontinuation or stepping down attempt.  98 
Covariates 99 
We abstracted data on patients’ age at the index date (in 10-year age bands), gender, and 100 
socioeconomic status (derived through linking CPRD to the Index of Multiple Deprivation 101 
(IMD) 2007). For each course, the potential indications as specified in the BNF 25 were 102 
identified by the presence of relevant Read codes on the first prescription date of a course, 103 
or within 30 days before and 12 month after that date. We considered prevention and 104 
treatment of NSAID-associated ulcer the indication if NSAID prescription date fell on the 105 
same date as the PPI prescription. Potential indications were then classified into 8 categories 106 
(supplementary Table1) and missing initial indication was recorded in a separate category.  107 
Statistical analysis 108 
Prevalence of PPI use 109 
For each year we calculated the period prevalence by dividing the number of patients who 110 
received at least one PPI prescription during that year by the corresponding mid-year adult 111 
population of the CPRD. We also calculated annual point prevalence as the number of 112 
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patients with an ongoing PPI prescription on 30th June divided by the corresponding mid-113 
year population. We stratified these prevalence estimates by gender and age (calculated on 114 
June 30th and grouped into 10 years age bands). 115 
Patterns of PPI use 116 
The baseline patient characteristics and the use of PPIs among new users were described as 117 
proportions of age bands, genders and quintiles of IMD (to represent socioeconomic status). 118 
We calculated the percentage of patients who continued their first PPI course, from the index 119 
date to the end of five years of follow-up during the study period. 120 
Kaplan Meier survival curves were constructed among all new PPI patients to 121 
graphically describe: 1) time to discontinuation (permanent or temporary) of the first PPI 122 
course during the five years follow-up, 2) time to permanent discontinuation of all PPI 123 
therapy during the five years follow-up. Time to discontinuation of the first PPI course was 124 
calculated from the index date to the first PPI course‘s end date. Time to permanent 125 
discontinuation was calculated from the index date to the end date of the last PPI course that 126 
each patient received during the follow-up period.  127 
The proportions of patients, who stepped down, or substituted PPIs, were calculated 128 
for long-term users as NICE guidelines13 recommends  reviewing long-term PPI user on an 129 
annual basis at a minimum. To determine successful step down attempts accurately patients 130 
were required to have a 12 month window after the step down date.  The analysis of 131 
successful step down attempts was therefore limited to patients who had stepdown 132 
attempts within the first 4 years of the follow-up to allow adequate follow up within the final 133 
year of the cohort. We repeated this analysis restricted to patients who started PPI therapy 134 
as long-term and whose indication might not suggest an ongoing need for long-term PPI use, 135 
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therefore patients with recorded indication of complicated GORD, NSAID-associated ulcers 136 
prophylaxis or reducing the degradation of pancreatic enzyme supplements were excluded.  137 
Analyses were performed using STATA 12 (Stata Corp, College Station, Texas).138 
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RESULTS 139 
Prevalence of prescribing 140 
We identified 31,956,396 PPI prescriptions in 1,828,141 adult patients during the study 141 
period. The point and period prevalence of PPI increased between 1990 and 2014 (Figure 1-142 
a) and it varied substantially by age group (Figure 1-b). The point prevalence of PPI use was 143 
similar between males and females, increasing during the study period from 0.04% in 1990 to 144 
7.05% in 2014 in males, and from 0.03% in 1990 to 8.35% in 2014 in females. The female to 145 
male prevalence ratio of PPI use was 1.14 (95% confidence intervals (CI) 1.12-1.17) from 146 
1990 to 2014. 147 
Prescribing patterns  148 
During the study period, 596,334 new users of PPI therapy with at least five years of follow-149 
up data were identified. Their mean age was 54.2 years (Standard Deviation SD: 16.3) and 150 
55% were females. They received a total of 8,784,272 prescriptions and 26.5% had one PPI 151 
prescription recorded. The median duration for all PPI prescriptions was 28 days 152 
(interquartile range (IQR) 18-56 days). 153 
Individual prescriptions were combined to create 1,708,513 PPI courses. The median 154 
duration of all courses was 55 days (IQR 28-125 days) and there were a median of 2 courses 155 
per patient (IQR 1-4 courses). Patients received prescriptions for enough PPI to cover 96.69% 156 
(95%CI 96.68-96.71) of days in these courses. 157 
 1,505,758 (88.1%) of the courses were categorised as short courses and 202,755(11.8%) 158 
were categorised as long courses with median durations of 28 days (IQR 28-79 days) and 805 159 
days (IQR 526-1345 days) for short and long courses respectively. 73.2% of the cohort 160 
received exclusively short courses with a mean age of 51.6years (SD 16.3 years), and 26.7% 161 
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received at least one long course with a mean age of 61.2years (SD 14.3 years)(Table 1).  162 
Within this cohort, 230,766 patients (38.7%) had only one PPI course, and 365,568 (61.3%) 163 
patients had multiple courses. Around 16.3% and 11.4% of patients remained continuously 164 
on PPI therapy for 6 and 12 months from their index date, respectively. At the end of 5 years 165 
of follow-up, 23,607 (3.9%) patients had remained on PPI continuously from the index date.  166 
Prescription indications  167 
Initially, 365,481 PPI courses (21.3%) had no coded indication for PPI prescription. This fell to 168 
14.0% after assuming prescriptions concurrent with NSAID prescriptions were intended for 169 
gastro-protection. Dyspepsia was the most frequent recorded indication (Table2). 170 
Discontinuation, step-down, and substitution 171 
Figure 2 shows the proportion of patients who discontinued the first PPI course (Figure 2-A), 172 
and patients who permanently discontinued all PPI courses (Figure 2-B). When considering 173 
only long-term PPI patients, 25% had temporarily discontinued their therapy at one year and 174 
three months after starting their long-term PPI course, 50% at one year and seven months 175 
and by two years and three months 75% had temporarily discontinued their long term PPI 176 
course. Of those discontinuing, 9,557 (9%) received a prescription for H2RA within one 177 
month before or after this occurred.  178 
Of the 159,259 patients who received long term PPIs, 63,640 (39.9%) had an attempt to 179 
step down their PPI dose (Table3). Of these 6,388 (10%) had received an H2RA prescription 180 
within one month before or after stepping down PPI dose. 181 
Of 59,734 patients in whom the initial indication for PPI prescription did not suggest a 182 
recognised need for PPI use to be prolonged, un-complicated GORD was the most frequent 183 
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recorded indication and  39,164 (65.5%) discontinued PPI therapy (temporarily or 184 
permanently). For those patients who temporarily discontinued their PPI therapy the median 185 
time to this was 3 years and 3 months after starting their PPI course. In those using PPI long 186 
term without recognised indication for such use a step down attempt was identified in 47% 187 
(Table4).188 
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DISCUSSION 189 
Summary  190 
This study describes the pattern of PPI prescription in UK general practice in terms of its 191 
prevalence and the practices employed to reduce long-term use. The proportion of the 192 
population using PPIs within each year increased from 0.2% in 1990 to 15.0% in 2014. Of 193 
those new PPI users who had five years of follow up available, 26.7% used PPI therapy for 194 
more than one year, and 3.9% remained on PPI therapy for five full years. Clear attempts to 195 
step down long-term use were identified in about 39%, and 8.7% of long-term users received 196 
a H2RA prescription around the time they attempted to step down and/or discontinue their 197 
use of PPI. Amongst patients whose initial PPI prescription indication did not necessarily 198 
warrant long term PPI use, 47% had attempts to step down their PPI dose.  199 
Comparison with previous work 200 
Our findings pertaining to the prevalence of PPI use in the early years of our study were 201 
consistent with the findings of earlier studies involving general practice in the UK14,16,18,26 in 202 
addition, our result revealed that the use of PPI has continued to rise. These trends are not 203 
limited to the UK: similar increases in prescription rates have been observed in the United 204 
States27, Australia28, and many European countries. This widespread increase supports the 205 
evidence that PPI prescriptions remain highly prevalent in many healthcare systems despite 206 
the extensive literature that indicates overprescribing PPI in both the primary and secondary 207 
care setting29,30. 208 
In this study, the proportion of patients who were on long-term PPI (26%) was higher 209 
than that reported in previous studies16–18, which have reported rates of long-term PPI usage 210 
between 0.05% and 4.4%, according to varying definitions of long-term use. Studies have 211 
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shown that repeat prescription practices account for approximately 32 to 81% of the total 212 
cost of prescribed drugs31. The continuous increase in PPI use, specifically the increase in the 213 
proportion of long-term users, may therefore have important cost implications despite the 214 
availability of low-cost PPI. 215 
PPIs provide effective symptomatic relief for patients who suffer from dyspepsia 216 
symptoms. However, while clinical guidelines suggest the use of PPI therapy over short 217 
durations to treat dyspepsia symptoms13, it seems that  PPIs had been prescribed as a form 218 
of maintenance therapy without specific underlying cause. Our study revealed that dyspepsia 219 
symptoms were the initial indication in 23% of long-term PPI courses. However, as most 220 
patients on first presentation in primary care will not have a final endoscopic diagnosis, it is 221 
inevitable that the GPs will have recorded less-specific indications in subjects who had other 222 
underlying diagnoses. Our results concur with those of several  studies that have reported 223 
that the majority of patients on PPI therapy are prescribed PPI for the purpose of relieving 224 
symptoms without any other clear indications32,33. In addition, although its clinical relevance 225 
is unproven, it has been proposed that rebound acid hypersecretion following PPI therapy 226 
withdrawal may help perpetuate the use of PPIs in patients with uncertain indications or who 227 
have received them for symptomatic relief of relatively mild symptoms for more than six 228 
weeks 34.  The issue of appropriateness in terms of prescription practices has been discussed 229 
in existing literature29,35,36. Despite this, PPIs are still being administered to patients for a 230 
variety of complaints that are not known to be acid-induced and over a long-term basis.  231 
In the view of the emerging concerns regarding adverse events from long-term PPI 232 
use, clinical guidelines13 have encouraged GPs to use PPIs carefully and to continually review 233 
long-term patients to try to step down or stop treatment. Our results suggest that GPs are 234 
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actively attempting to reduce PPI use by stepping down and substituting alternative 235 
medication. Previous studies36–39 reported discontinuation rates that differed from those 236 
identified in our study; however, these can be explained by variations in the study population 237 
and the discontinuation strategies employed38. Reports regarding the outcomes of step-238 
down therapy have been conflicting40,41. For example, one study reported that more than 239 
half of the patients involved in the study remained asymptomatic after the step down41 while 240 
another reported that  19% of patients whose PPI therapy was stepped down experienced 241 
relapsed symptoms and resumed PPI use40. In our study, 60% of the long-term PPI users 242 
maintained lower doses for more than one year. However, while we identified an appreciable 243 
proportion of long-term PPI users who could potentially reduce the use of the drug, we were 244 
unable to find evidence of such attempts in a large proportion of those individuals. Non-245 
adherence to the step down therapy, therefore, allows the maintenance of inappropriate PPI 246 
prescription which may sustains overuse of PPIs.  247 
Strengths and limitations 248 
Our study used data from a large database of UK primary care records which has been 249 
extensively used and validated for pharmacoepidemiological research21,24. The population in 250 
our study is therefore representative of the general practice population of the UK to whom 251 
our results should be generalizable21. The large sample size has allowed us to stratify our 252 
analyses by age groups and gender, and to show trends in PPI use over time. It has also 253 
provided us with adequate power to identify the relatively small proportion of patients who 254 
took PPIs on a long-term basis and describe the management of their prescriptions.  255 
Weaknesses in our study include that we may have underestimated PPI use since neither 256 
hospital prescriptions nor over the counter (OTC) use are captured in the data. However, 257 
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since secondary care initiated PPI treatment will often be continued by GPs afterwards35, and 258 
prescribed PPI use continued to rise after they became available OTC 42 we think it unlikely 259 
that this has led to massive underestimation. Additionally, we focused on long-term users 260 
who would be the most likely to obtain their prescriptions from their GPs. Furthermore, the 261 
period of PPI exposure for those who took PPI intermittently may have been underestimated, 262 
since the calculation of the prescription duration was based on the assumption that the 263 
dispensed prescription was consumed as directed. Indeed, CPRD only contains information 264 
about the prescriptions of medications; as such, it is not possible to assess whether patients 265 
actually collected or consumed the prescribed medication. In addition, our definition of a 266 
successful stepdown may underestimate the proportion of patients whose long-term PPI 267 
therapy was stepped down but then required a smaller increase in dose lower than the initial 268 
dose. However, including this in our definition only identified an additional 997 patients (an 269 
additional1.5% of attempted step downs) so for clarity we retained our initial stricter 270 
definition. Furthermore, our method of estimating successful step down attempts within the 271 
initial 4 years of follow-up would not have led to a substantial underestimation, as it is 272 
expected that long-term patients should have been offered a step down attempt at least 273 
within the first year of their continuous use of PPI therapy.274 
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CONCLUSION: 275 
During the study period, a considerable increase in the administration of PPI prescriptions 276 
was observed in UK general practice. The majority of patients use PPIs on a short-term basis 277 
with 26% of the identified use long term. Our results suggest that GPs are actively attempting 278 
to decrease the use of PPI by stepping down and discontinuing prescriptions; however, this is 279 
not universally practised, nor is it always successful when attempted. If the cost and potential 280 
risks of the continuing increase of PPI are to be minimised, a proactive clinical review and 281 
adherence to the guidelines is likely to be required. 282 
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Tables and figures: 
Table 1: Descriptive characteristics of new users of proton pump inhibitor (PPI) therapy with ≥ 5 years of follow-up 
data( patients with  exclusively short-term courses and patients with at least one long-term course), and the duration 
(in days) for the first short and long courses. 
IQR=interquartile range 
** Socioeconomic status is based on Index of multiple deprivations (IMD) and figures are percent of the people 
who have available deprivation status
 Total number  Patients with exclusively short 
course 
 
Patients with at least one long 
course in their records 
 
Patients 
characteristics 
N=596,334 N=437,075 Duration of 
first short 
course 
N=159,259 Duration of first 
long course 
  % Number % Median(IQR) Number % Median(IQR) 
Age         
18-30 50,318 8.4 46,683 92.7 28(28-28) 3,635 7.2 705(484-1172) 
31-40 83,579 14.1 72,475 86.7 28(28-49) 11,104 13.2 769(502-1314) 
41-50 113,746 19.1 91,721 80.6 28(28-56) 22,025 19.3 816(524-1403) 
51-60 120,553 20.3 86,466 71.7 28(28-56) 34,087 28.2 876(544-1491) 
61-70 115,470 19.4 73,854 63.9 28(28-56) 41,616 36.0 935(568-1568) 
71-80 80,968 13.6 48,034 59.3 28(28-56) 32,934 40.6 978(582-1610) 
>80 27,997 4.7 15,216 54.3 28(28-59) 12,781 45.6 1014(592-1656) 
Gender         
Male 262,765 44.0 190,947 72.6 28(28-56) 71,818 27.3 920(559-1556) 
Female 333,569 55.9 246,128 73.7 28(28-56) 87,441 26.2 882(546-1496) 
Index of Multiple 
Deprivation** 
(quintiles) 
        
Unavailable 263,562 44.2 191,426 72.6 28(28-56) 72,136 27.3 905(553-1530) 
1(least deprived) 75,711 12.7 57,276 75.6 28(28-56) 18,435 24.3 865(538-1467) 
2 78,619 13.1 57,893 73.6 28(28-56) 20,726 26.3 894(550-1512) 
3 66,880 11.2 48,987 73.2 28(28-56) 17,893 26.7 905(555-1532) 
4 64,654 10.8 47,256 73.0 28(28-56) 17,398 26.9 914(561-1535) 
5(most deprived) 46,908 7.8 34,237 72.9 28(28-53) 12,671 27.0 908(557-1574) 
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 Table 2: Recorded indication for all  proton pump inhibitor(PPI)courses( all short courses in exclusively 
short-term PPI  users and all long courses in patients with at least one long-term PPI course). 
* column percentage; GORD= Gastro-oesophageal reflux disease; NSAID nonsteroidal anti-
inflammatory drugs 
 
 
Total number 
 
N=596,334 
 Patient with exclusively short 
courses 
N=437,075 
Patients who had at least 
one long-term course 
N=159,259 
Indication category  All PPI courses 
1,708,513 
%*  Short PPI courses 
1,158,705 
%* Long PPI courses 
202,755 
%* 
Dyspepsia 612,842 35.8 452,651 39.0 47,086 23.2 
un-complicated GORD  495,288 28.9 309,204 26.6 70,485 34.7 
NSAID prophylaxis 132,426 7.7 90,380 7.8 17,926 8.8 
Gastritis &duodenitis 125,300 7.3 73,089 6.3 23,037 11.3 
peptic ulcer below 
oesophagus 
51,137 2.9 27,871 2.4 10,356 5.1 
Helicobacter therapy   24,466 1.4 18,755 1.6 1,581 0.7 
GORD complicated 13,146 0.7 5,464 0.4 2,935 1.4 
Reduction of pancreatic 
enzyme degradation 
3,450 0.2 1,924 0.1 560 0.2 
missing 250,458 14.0 179,367 15.4 28,789 14.2 
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Table 3:  Numbers and percentages of long-term proton pump inhibitor (PPI) users who attempted a 
step down in dose, were successful at 12 months, and were prescribed histamin2 receptor antagonists 
(H2RA) by age, time, and indication. 
GORD=Gastro-oesophageal reflux disease; NSAID= non-steroidal anti-inflammatory drugs 
H2RA=Histamine 2 Receptor antagonist 
*percentages were calculated from the total number of long-PPI patients 
** percentages were calculated from the number of step down patients  who stepped down within 
the first 4 years of follow-up and successfully stepped down for 12 months(number of patients 
(59,458))
 Patients 
with at 
least one 
long PPI 
course 
Number of patients 
who had step down 
to lower PPI dose 
Number of patients 
who maintained 
lower dose after 
step down attempt 
for 12 months** 
Number of patients who 
received H2RA 
substitution at time of 
step down and /or 
discontinuation 
 Number %* Number % Number %* 
 159,259 63,640 39.9 36,006 60.5 13,954 8.7 
Age group        
18-30     3,632 1,559 42.9 695 47.7 315 8.6 
31-40 11,095 4,774 43.0 2,344 52.5 910 8.2 
     41-50 22,001 9,127 41.4 4,720 55.5 1,568 7.1 
51-60 34,040 14,037 41.2 7,777 59.5 2,611 7.6 
61-70 42,822 17,205 40.2 9,892 61.5 4,042 9.4 
71-80 32,917 12,503 37.9 7,766 66.3 3,271 9.9 
>80 12,752 4,435 34.7 2,812 67.9 1,237 9.7 
Time when GP attempt to 
step down 
       
2 month  25,240 39.6 18,536 73.5 3,986 15.7 
6 month  14,414 22.6 8,152 57.7 1,722 11.9 
12 month  9,171 14.4 3,819 45.7 6,295 6.0 
More than 12 month  14,815 23.2 5,474 46.8 1,951 13.1 
Indication        
GORD un-complicated 55,450 26,402 47.6 14,674 59.2 6,125 11.0 
Dyspepsia 37,011 14,897 40.2 8,802 63.2 3,203 8.6 
Gastritis &duodenitis 18,383 7,889 42.9 3,656 50.3 1,968 10.7 
NSAID prophylaxis 13,695 3,591 26.2 2,575 75.9 537 3.9 
peptic ulcer below 
oesophagus 
8,188 3,838 46.8 2,306 63.6 780 9.5 
GORD complicated 2,209 675 30.5 380 60.8 124 5.6 
Helicobacter therapy 1,257 444 35.3 238 57.0 99 7.8 
Reduction of pancreatic 
enzyme degradation 
416 129 31.0 59 48.7 28 6.7 
missing 22,650 5,775 25.5 3,316 62.2 1,090 4.8 
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Table 4 : Numbers and percentages of long-term proton pump inhibitor (PPI) users who attempted a 
step down in dose, were successful at 12 months, and were prescribed histamin2 receptor antagonists 
(H2RA) by age, time, and indication. Analysis restricted to indications unsuitable for step down. 
GORD=Gastro-oesophageal reflux disease; H2RA=Histamine 2 Receptor antagonist 
* percentages were calculated from the total number of long-PPI patients 
** percentages were calculated from the number of step down patients  who stepped down within the first 
4 years of follow-up and successfully stepped down for 12 months(number of patients (27,473)) 
 
  Patients with at 
least one long 
proton pump 
inhibitor course 
 
Number of patients 
who had step down 
to lower PPI dose 
Number of patients 
who maintained lower 
dose after step down 
attempt for 12 
months** 
Number of patients 
who received H2RA 
substitution at time 
of step down and /or 
discontinuation 
 Number %* Number % Number %* 
 59,734 28,113 47.0 16,907 61.5 5,567 9.3 
Age group        
18-30 1,075 569 52.9 282 50.2 105 9.7 
31-40 3,586 1,912 53.3 969 51.4 299 8.3 
41-50 7,648 3,783 49.4 2,110 56.8 593 7.7 
51-60 12,417 6,063 48.8 3,519 59.2 1,003 8.0 
61-70 16,347 7,675 46.9 4,679 62.4 1,603 9.8 
71-80 13,254 5,902 44.5 3,870 67.4 1,413 10.6 
>80 5,407 2,209 40.8 1,478 69.0 551 10.1 
Time when GP attempt to 
step-down 
       
2 month  11,602 41.2 8,323 71.7 2,019 17.4 
6 month  6,922 24.6 4,157 60.0 2,339 6.0 
12 month  3,407 12.1 1,683 49.4 433 12.7 
More than 12 month  6,182 21.9 2,744 49.5 776 12.5 
Indication        
GORD un-complicated 22,173 12,290 55.4 7,290 60.4 2,524 11.3 
Dyspepsia 13,686 6,426 46.9 4,116 65.5 1,268 9.2 
Gastritis &duodenitis 7,761 3,731 48.0 1,948 53.5 791 10.1 
peptic ulcer below 
oesophagus 
4,126 2,101 50.9 1,343 65.4 396 9.6 
Helicobacter therapy 402 192 47.0 111 59.0 35 8.7 
missing 11,586 3,373 29.1 2,099 64.5 553 4.7 
